Ultragenyx Pharmaceutical (RARE) Return on Sales (2016 - 2026)

Ultragenyx Pharmaceutical (RARE) has 11 years of Return on Sales data on file, last reported at 0.01% in Q1 2026.

• Quarterly Return on Sales changed 0.0% year-over-year to 0.01% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.01% (down 1.0% YoY) and the FY2025 annual result came in at 0.01%, down 1.0% from the prior year.
• Return on Sales slipped to 0.01% in Q1 2026 per RARE's latest filing, from 0.01% in the prior quarter.
• Across five years, Return on Sales topped out at 0.03% in Q4 2024 and bottomed at 0.03% in Q3 2022.
• The 5-year median for Return on Sales is 0.01% (2026), against an average of 0.01%.
• The widest annual swing landed in 2024, when Return on Sales advanced 4 bps; it then slipped 3 bps in 2025.
• Tracing RARE's Return on Sales over 5 years: stood at 0.01% in 2022, then surged by 35 bps to 0.01% in 2023, then surged by 368 bps to 0.03% in 2024, then slumped by 124 bps to 0.01% in 2025, then tumbled by 119 bps to 0.01% in 2026.
• Per Business Quant, the three latest RARE Return on Sales figures stand at 0.01% (Q1 2026), 0.01% (Q4 2025), and 0.01% (Q3 2025).

Peer Comparison